EMERYVILLE, Calif.--(BUSINESS WIRE)--Scientists at KineMed, Inc., describe a new way to measure changes in the rates of deposition and breakdown of connective tissue applicable in animals and man. The methods described fill a critical need for better approaches to enable the discovery and development of drugs to treat a range of life-threatening diseases in which excessive deposition of collagen leading to organ dysfunction (fibrosis) plays a key role. Such advances can facilitate clinical trials for better treatments for such conditions as scleroderma, cirrhosis, pulmonary fibrosis and chronic transplant rejection.
